<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128218</url>
  </required_header>
  <id_info>
    <org_study_id>COZ-SIU 10-002-1</org_study_id>
    <nct_id>NCT01128218</nct_id>
  </id_info>
  <brief_title>A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors</brief_title>
  <official_title>A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Illinois University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extent of resection is a very important prognostic factor affecting survival in individuals
      diagnosed with a malignant glioma. However, the infiltrative nature of the malignant glioma
      tumor cells produces indistinct borders between normal and malignant tissues, and the lack of
      easily identifiable tumor margins confounds attempts at total resection. The investigators
      propose to identify the borders of malignant gliomas intraoperatively using oral
      5-aminolevulinic Acid (5-ALA) which results in fluorescence of the malignant cells and
      thereby provide an opportunity for more complete tumor resection.

      When exogenous 5-ALA is provided at increased concentration the tumor cells will become
      fluorescent under ultraviolet light. This feature identifies the tumor cells intraoperatively
      and facilitates complete resection.

      Data collection will include measurement of dose-limiting toxicity, tumor fluorescence, and
      tumor density. Data analysis will evaluate toxicity, sensitivity, and specificity of 5-ALA.
      Time-to-progression, one year survival rate and total survival will be measured as a function
      of the extent of resection. (Details below in Detailed Description.)

      Following completion of the phase 1 portion of this trial, an additional 15 subjects will be
      entered at the recommended phase 2 dose level in order to further define the above parameters
      at the recommended phase 2 dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      This study is intended to investigate the utility, safety and efficacy of 5-aminolevulinic
      acid (5-ALA) induced brain tumor fluorescence during malignant brain tumor resection.
      Specifically this study is intended to:

      Establish a safe dose for oral 5-ALA administration. Determine the sensitivity and
      specificity of 5-ALA mediated fluorescence for malignant glioma tissue in the brain.

      Compare the neurosurgeon's intra-operative estimate of the extent of malignant glioma
      resection (as guided by tumor fluorescence) with the actual extent of resection determined by
      post-operative imaging.

      Compare time-to-progression and survival to that in comparable cases performed without the
      aid of 5-ALA.

      Background and Significance:

      There is a considerable body of literature that suggests that completeness of resection is a
      positive factor for longer term survival in individuals with malignant glioma. Unfortunately,
      it is often difficult to completely remove a malignant brain tumor because during surgery it
      is sometimes very difficult to distinguish tumor from normal brain. It would be very helpful
      if there would be some way to help the surgeon make this distinction. Malignant glioma tumor
      cells (more so than normal cells) contain the biosynthetic pathways to produce protoporphyrin
      from a naturally occurring amino acid, 5-aminolevulinic acid (5-ALA). Protoporphyrin is the
      immediate precursor to hemoglobin (it is hemoglobin without the iron atom) and is fluorescent
      under blue light. When exogenous 5-ALA is provided at increased concentration, protoporphyrin
      concentration in the malignant cell increases at a rate far greater than normal brain cells
      and renders the malignant cell fluorescent red under blue light. This feature distinguishes
      the tumor cells from normal cells intraoperatively and facilitates complete resection.

      Recent studies in Germany have confirmed the utility of pre-operative oral 5-ALA and
      intraoperative brain tumor fluorescence in aiding the resection of brain tumors in
      individuals with malignant brain tumors. These studies have led to oral 5-ALA to be approved
      for this indication by the European Medicines Agency (The European Medicines Agency comments
      and approval can be found at:
      http://www.emea.europa.eu/humandocs/PDFs/EPAR/gliolan/H-744-en6.pdf), but oral 5-ALA has not
      been approved for this indication by the United States FDA. This proposal is a phase 1 and
      phase 2 trial that will hopefully lead to FDA approval of oral 5-ALA for intra-operative
      visualization of malignant brain tumors.

      Experimental Plan and Methods:

      In the phase 1 part of this proposed study, a minimum of 3 to a maximum of 18 patients will
      be administered oral 5-ALA 4 hours prior to surgery in cohorts of 3 at five escalating doses
      of 5-ALA (10, 20, 30, 40, or 50 mg/kg).

      The following data will be collected:

        -  Dose-limiting toxicity data; i.e., nausea, vomiting, liver function, photo-sensitivity,
           survival

        -  Tumor fluorescence assessed by neurosurgeon (0 to +++) in three distinct areas of
           fluorescence (Strong fluorescence, Weak fluorescence, No fluorescence)

        -  Tumor density from biopsies obtained by the neurosurgeon in the same three distinct
           areas of fluorescence and assessed by neuropathology (Solid tumor, Tumor mixed
           infiltrating normal brain, No tumor)

        -  Neurosurgeon's intra-operative estimate of residual tumor

        -  Neuroradiologist's estimate of post-operative residual tumor on MRI

        -  Time to progression by MRI

        -  Survival (time to progression, one year survival rate and total survival)

      This trial will evaluate:

        -  single dose toxicity of oral 5-ALA given pre-operatively;

        -  sensitivity and specificity of 5-ALA - Protoporphyrin IX (Pp IX) as an intraoperative
           fluorescent detection agent and aid for resection of tumor tissue remaining in the walls
           of the resection cavity of primary and recurrent malignant brain tumors;

        -  relationship of the neurosurgeon's estimate of the extent of malignant glioma resection
           (as guided by tumor fluorescence) to the actual extent of resection determined by
           post-operative imaging;

        -  time-to-progression, one year survival rate and total survival as a function of the
           extent of resection.

      Following completion of the phase 1 portion of this trial, an additional 15 subjects will be
      entered at the recommended phase 2 dose level in order to further define the above parameters
      at the recommended phase 2 dose level.

      Discussions statisticians have led to the development of a number of 2x2 tables and 3x3
      tables of data analysis that will lead to establishment of the sensitivity and specificity of
      fluorescence-guided brain tumor resection compared to conventional brain tumor resection
      techniques.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Change in the following factors will be continually reviewed between baseline and 6 months: nausea and vomiting; liver function; photo-sensitivity; survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor fluorescence intra-operative assessment by neurosurgeon</measure>
    <time_frame>baseline</time_frame>
    <description>During surgery, neurosurgeon will assess tumor fluorescence (0 to +++) in three distinct areas of fluorescence (Strong fluorescence, Weak fluorescence, No fluorescence) to determine level of 5-ALA mediated fluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor fluorescence intra-operative assessment by neurosurgeon</measure>
    <time_frame>24 months</time_frame>
    <description>During surgery, neurosurgeon will assess tumor fluorescence (0 to +++) in three distinct areas of fluorescence (Strong fluorescence, Weak fluorescence, No fluorescence) to determine level of 5-ALA mediated fluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor density determined by post-operative imaging</measure>
    <time_frame>baseline</time_frame>
    <description>Tumor density from biopsies obtained by the neurosurgeon will be assessed by neuropathology (Solid tumor, Tumor mixed infiltrating normal brain, No tumor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor density determined by post-operative imaging</measure>
    <time_frame>24 months</time_frame>
    <description>Tumor density from biopsies obtained by the neurosurgeon will be assessed by neuropathology (Solid tumor, Tumor mixed infiltrating normal brain, No tumor).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tumor fluorescence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tumor fluorescence</intervention_name>
    <description>oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg</description>
    <arm_group_label>Tumor fluorescence</arm_group_label>
    <other_name>5-ALA</other_name>
    <other_name>5-aminolevulinic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have clinically documented primary brain tumor for which resection is
             clinically indicated.

          -  Age â‰¥ 18 years. Because no dosing or adverse event data are currently available on the
             use of 5-ALA in patients &lt;18 years of age, children are excluded from this study but
             will be eligible for future pediatric phase 1 single-agent trials

          -  ECOG performance status &lt;2 (Karnofsky &gt;60%)

          -  Normal organ and marrow function as defined below:

               -  Leukocytes &gt; 3,000/mcL

               -  Absolute neutrophil count &gt; 1,500/mcL

               -  Platelets &gt; 100,000/mcL

               -  Total bilirubin within normal institutional limits AST (SGOT)/ALT (SGPT) &lt; 2.5 X
                  institutional upper limit of normal

               -  Creatinine within normal institutional limits OR Creatinine clearance &gt; 60
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal

          -  Agreement by women of child-bearing potential and men to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents at the time of entry
             into the study

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to 5-ALA

          -  Personal or family history of porphyrias

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study because 5-ALA is of unknown teratogenic or
             abortifacient effects. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother with 5-ALA,
             breastfeeding should be discontinued if the mother is treated with 5-ALA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey W Cozzens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Illinois University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/braincancer.html</url>
    <description>Brain Cancer</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/cancer.html</url>
    <description>Cancer</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0000106605&amp;QV1=AMINOLEVULINIC+ACID</url>
    <description>Aminolevulinic Acid</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0005451092&amp;QV1=AMINOLEVULINIC+ACID+HYDROCHLORIDE</url>
    <description>Aminolevulinic Acid Hydrochloride</description>
  </link>
  <reference>
    <citation>Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol. 1999 Oct;52(4):371-9.</citation>
    <PMID>10555843</PMID>
  </reference>
  <reference>
    <citation>Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6. doi: 10.1227/01.neu.0000318159.21731.cf. Review.</citation>
    <PMID>18496181</PMID>
  </reference>
  <reference>
    <citation>Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 May;7(5):392-401.</citation>
    <PMID>16648043</PMID>
  </reference>
  <reference>
    <citation>Tonn JC, Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg. 2008;55:20-6. Review.</citation>
    <PMID>19248665</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Neoplasms</keyword>
  <keyword>5-ALA</keyword>
  <keyword>Aminolevulinic acid</keyword>
  <keyword>Fluorescence</keyword>
  <keyword>Gliomas</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

